Reut is a Managing Director at aMoon. A scientist by training, she uses her extensive knowledge and broad network from over a decade of experience at Harvard, MIT, and the Weizmann Institute, to source and lead investments in innovative companies that bring cutting-edge science to market.
Reut joined aMoon in May 2018, and is one of the leaders of aMoon Edge, our public equity fund. At Edge, she applies a differentiated lens to public equity investing that emphasizes a fundamental-based ownership mindset in under-valued companies. Prior to Edge, Reut led investments in Satellite Bio and Omada Health, and has played an essential role in several of aMoon’s other investments, including Ultima Genomics, Seer, and SOPHiA Genetics.
Before joining aMoon, Reut was a VP of Business Development and scientific advisor at Greenfield Partners, a TPG growth investment platform. She also served as an advisor to several prominent international investors and co-founded a healthcare company.
Reut has over 10 years of experience in groundbreaking research and has won numerous grants and awards for her work. She was a postdoctoral fellow at MIT’s Broad Institute and at Harvard, where she led a project to develop an innovative platform for evaluating therapeutics for psychiatric diseases. Her study of aging and neurodegenerative disease was published in PNAS, the peer-reviewed journal of the National Academy of Sciences, and led to the development of a novel in vivo screening method.
Reut completed her PhD at the Weizmann Institute of Science, where she studied long-term memory maintenance in the brain. Her work has contributed greatly to the field and is summarized in three papers, including two in the prestigious journal Science. She holds a BSc in Biology and Psychology (Magna Cum Laude) from Tel Aviv University.